Drugs in the Pipeline, News
FDA Issues EUA to Baricitinib Plus Remdesivir for Hospitalized COVID-19 Patients
The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.
Your search for supplemental oxygen returned 9 results
Drugs in the Pipeline
NIH: Remdesivir Plus Interferon Beta-1a Being Evaluated for COVID-19
The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.
Drugs in the Pipeline
Trials Testing Convalescent Plasma for COVID-19 Expanded
Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.
Drugs in the Pipeline
Mixed Results for Baricitinib in Trial of Hospitalized COVID-19 Patients
Findings showed that the trial did not meet statistical significance on the primary endpoint.
Drugs in the Pipeline
Baricitinib Plus Remdesivir Cuts Time to Recovery for Hospitalized COVID-19 Patients
The ACTT-2 study began on May 8 and included more than 1000 patients.
Drugs in the Pipeline
Tocilizumab Gets Priority Review for Treatment of Hospitalized COVID-19 Patients
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
Drugs in the Pipeline
Lenzilumab Promising for Hospitalized Patients With COVID-19
Lenzilumab is an investigational anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
Drugs in the Pipeline
Baricitinib Alone Authorized for COVID-19 Under Revised EUA
The update was based on data from the COV-BARRIER study.
Drugs in the Pipeline
Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
